Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

J. Nastoupil, Loretta; D. Jain, Michael; Feng, Lei; Y. Spiegel, Jay; Ghobadi, Armin; Lin, Yi; Dahiya, Saurabh; A. Lunning, Matthew; J. Lekakis, Lazaros; M. Reagan, Patrick; O. Oluwole, Olalekan; P. McGuirk, Joseph; Deol, Abhinav; R. Sehgal, Alison; Goy, André; T. Hill, Brian; Vu, Khoan; Andreadis, Charalambos; Muñoz, Javier; R. Westin, Jason; C. Chávez, Julio; F. Cashen, Amanda; Nora Bennani, N.; P. Rapoport, Aaron; M. Vose, Julie; B. Miklos, David; S. Neelapu, Sattva; L. Locke, Frederick

doi:10.1200/jco.19.02104

Public

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Published in Journal of Clinical Oncology • May 13, 2020

Authors:

Loretta J. Nastoupil

Michael D. Jain

Lei Feng

Abstract

PURPOSE: Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infuse...

Subject

Medicine

Leukapheresis

Cytokine release syndrome

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!